Short answer
MYRIAD GENETICS INC (MYGN) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Myriad Genetics announced financial results for the three months ended September 30, 2026.
MYRIAD GENETICS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Myriad Genetics announced financial results for the three months ended September 30, 2026
- Detailed results and management commentary appear in Exhibit 99.1, the attached earnings release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $202.7M, down 1% YoY, while average revenue per test rose 1% as payer and revenue-cycle initiatives gained traction
- Core Cancer Care Continuum and Mental Health volume increased 3% YoY to 239,000 tests, offset by Prenatal volume declining 11%
- Prenatal Health sale to Labcorp for $210M cash plus inventory expected by early 2027, concentrating Myriad on higher-priority oncology and mental-health businesses
- Q3 operating loss widened to $39.9M from $23.3M, with gross margin falling to 67.9% from 69.9%
- FY2026 revenue guidance midpoint raised to approximately $785M, including $620M-$630M from continuing businesses and approximately $160M Prenatal revenue
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MYRIAD GENETICS INC 8-K filings
Get the next MYGN 8-K as it lands
Follow MYGN for push alerts, or ask the research agent what this filing means.